Hester Biosciences Divests Remaining Stake in Texas Lifesciences

AHMEDABAD, India — Indian animal healthcare major Hester Biosciences Limited announced on Thursday, July 9, 2026, that it has successfully completed the divestment of its remaining equity investment in Texas Lifesciences Private Limited. The pharmaceutical firm executed the final transfer of its residual 11% stake to existing shareholders of the enterprise on July 8, 2026. The final cash consideration for the transaction was valued at INR 23 million, bringing Hester’s total equity ownership in the company to zero.

Complete Divestment and Transaction Structure

According to an official regulatory filing submitted to the BSE Limited and the National Stock Exchange of India Limited, Hester Biosciences offloaded 543,248 equity shares. This parcel represented exactly 11% of the total paid-up equity share capital of Texas Lifesciences Private Limited.

The corporate action was carried out under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. Board approval for the equity transfer was granted during a previous leadership assembly, authorizing corporate executives to conclude the exit framework with the counterparty shareholders at an agreed aggregate value of INR 23 million. Following this final equity transfer, Hester Biosciences holds no remaining corporate interests, operational liabilities, or equity investment in the firm.

Context and Shifting Strategic Priorities

The full exit from Texas Lifesciences highlights a strategic pivot by Hester Biosciences' management team to concentrate operational assets on core product lines. Headquartered in Ahmedabad, Gujarat, Hester Biosciences is recognized as one of India's largest manufacturers of animal biologicals, poultry vaccines, and large-animal healthcare formulations.

[Hester Biosciences Asset Reallocation]
Divestment of Secondary Formulations (Texas Lifesciences) -> Capital Reinvestment in Core Veterinary Biologicals

Texas Lifesciences originally functioned as a dedicated manufacturing partner, supplying generic pharmaceutical formulations, liquid orals, and external applications. By divesting from this peripheral manufacturing joint venture, Hester frees up internal capital to support its higher-margin veterinary biotechnology pipelines. This includes expanding its primary poultry vaccine facilities in Mehsana, Gujarat, and scaling up international distribution networks across Africa and Southeast Asia.

Impact on Shareholders and Market Outlook

The completion of the divestment provides financial clarity to public shareholders and institutional investors tracking Hester's capital allocation strategy. By liquidating non-core assets, the company adds immediate cash liquidity to its balance sheet without disrupting its main manufacturing or distribution operations.

-----------------------------------------------------------------------------------
| Financial & Deal Metric      |    Transaction Execution Value   |
-----------------------------------------------------------------------------------
| Total Consideration            |     INR 23 Million (All-Cash)        |
| Transferred Equity Units    |     543,248 Common Shares       |
| Proportional Capital Size   |     11% of Paid-up Capital           |
| Closing Shareholding        |      0.00% (Complete Exit)           |
-----------------------------------------------------------------------------------

For the animal health sector, the transaction shows a broader industry trend where specialized manufacturers are consolidating their corporate footprints. Investors responded neutrally to the filing, as the planned exit had been anticipated within the company's long-term business restructuring goals.

Official Sources Section

The regulatory details, transaction values, and asset ownership figures cited in this report are based entirely on official corporate disclosures issued by Hester Biosciences Limited on July 9, 2026. All financial data and compliance variables were drawn directly from verified statutory filings submitted to the National Stock Exchange of India Limited and signed by the company's compliance officer.

Executive Statements

"Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Company has transferred its remaining 543,248 equity shares representing 11% of the paid-up equity share capital of Texas Lifesciences Private Limited to existing shareholders on 8 July 2026. Consequent upon the aforesaid transfer, the Company's shareholding stands reduced from 11% to Nil and the Company no longer holds any equity investment."

— Vinod Mali, Company Secretary & Compliance Officer at Hester Biosciences Limited

Why It Matters

When a specialized biopharmaceutical firm divests its secondary holdings, it allows management to focus resources entirely on primary market segments. This transaction clarifies Hester's corporate structure and ensures that future capital expenditure is directed into core assets, such as advanced veterinary biologicals and pathogen research facilities, rather than non-core formulation plants.

Key Facts at a Glance

• The Divestment: Hester Biosciences has transferred all remaining equity shares held in Texas Lifesciences.

• Capital Transfer: The transaction involved 543,248 shares, representing an 11% block of the company's total paid-up equity capital.

• Financial Return: The transaction was completed for an aggregate cash consideration of INR 23 million.

• Total Position: Following the July 8 execution, Hester’s equity investment in Texas Lifesciences stands at Nil.

• Regulatory Compliance: The corporate update was formally filed under SEBI Listing Obligations and Disclosure Requirements.

Frequently Asked Questions

What was Hester Biosciences' total stake in Texas Lifesciences prior to this transaction?

Prior to the final execution on July 8, 2026, Hester Biosciences retained an 11% stake in the enterprise, which has now been reduced to zero.

Who acquired the 11% equity stake offloaded by Hester?

The 543,248 equity shares were transferred directly to existing internal shareholders of Texas Lifesciences Private Limited, in accordance with pre-approved corporate terms.

Where is Hester Biosciences Limited headquartered?

The animal healthcare enterprise maintains its primary corporate and registered operations in Mehsana, Gujarat, with its main executive offices located in Ahmedabad.

Source: Hester Biosciences Limited Investor Relations Desk, Company Disclosure to Stock Exchanges